Mirubedis (Rivaroxaban)

Rivaroxaban, the active ingredient in Mirubedis, is a Factor Xa inhibitor presented as an oral tablet for oral use. It treats and helps prevent clot formation in conditions such as non‑valvular atrial fibrillation, deep vein thrombosis and pulmonary embolism.

GNH USA supplies Mirubedis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirubedis, a direct Factor Xa inhibitor, is employed in several thrombo‑embolic conditions.

Non‑valvular atrial fibrillation: reduces the risk of stroke and systemic embolism. Deep vein thrombosis (DVT): treats acute clot formation and prevents extension. Pulmonary embolism (PE): manages acute embolism and lowers recurrence risk.

Common Side Effects: - Minor bruising or bleeding at sites of injury. - Nosebleeds (epistaxis). - Gastrointestinal discomfort such as dyspepsia. - Headache. - Mild anemia.

Serious or Rare Side Effects: - Major bleeding, including gastrointestinal or intracranial hemorrhage. - Spinal or epidural hematoma, especially after neuraxial procedures. - Severe allergic reactions (anaphylaxis, rash). - Hepatic injury or elevated liver enzymes. - Thrombocytopenia. - Unexplained sudden drop in blood pressure.

Before initiating therapy, clinicians should evaluate individual bleeding risk and renal function.

Assess renal function: adjust use in patients with impaired clearance. Monitor for bleeding: watch for signs of unexpected hemorrhage. Review concomitant antiplatelet or NSAID use: consider increased bleeding risk. Elderly patients: start at the lowest effective dose when appropriate. Active pathological bleeding: avoid use until bleeding is controlled. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Rivaroxaban may interact with several medicines that affect hemostasis or drug metabolism.

Major Interactions (Avoid): - Concurrent use with other anticoagulants (e.g., warfarin, heparin). - Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin). - Potent P‑glycoprotein inhibitors (e.g., cyclosporine, itraconazole). - Antiplatelet agents (clopidogrel, aspirin at high dose). - Non‑steroidal anti‑inflammatory drugs (high‑dose ibuprofen, naproxen).

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (diltiazem, verapamil). - Moderate P‑glycoprotein inhibitors (quinidine, amiodarone). - Selective serotonin reuptake inhibitors (fluoxetine, sertraline). - Herbal supplements such as ginkgo biloba or garlic. - Statins metabolized by CYP3A4 (atorvastatin, simvastatin).